#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chordoma Idiopathic pulmonary fibrosis Partial lipodystrophy Systemic scleroderma Non-Hodgkin's lymphoma Bronchiectasis Familial haemophagocytic lymphohistiocytosis Autoimmune demyelinating disease Spinal cord injury cervical Deafness Cardiac amyloidosis Orthostatic hypotension Li-Fraumeni syndrome Gaucher's disease type III Mastocytosis More trials…

    Learn about Rare Diseases

    Rett syndrome – Trials in Disease Paroxysmal nocturnal haemoglobinuria Alternating hemiplegia of childhood – Diagnostics Waldenstrom’s macroglobulinaemia – Basic Information Lymphangioma – Trials in Disease Small intestine leiomyosarcoma – Trials in Disease Antisynthetase syndrome – Diagnostics Pulmonary fibrosis – Treatment Medulloblastoma – Life with Disease Myelodysplastic syndrome with excess blasts – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Fluorescein Sodium Imidapril Hydrochloride Danicamtiv Falbikitug Xenon Demeclocycline Hydrochloride AGANIRSEN Dazostinag Neostigmine Methylsulfate Glucagon XELAFASLATIDE Tiotropium Bromide Monohydrate Emicizumab Tumour Detection ARGININE GLUTAMATE Sabestomig INSULIN DETEMIR Adg126 Xanthum Gum Specific Nucleic Acid Sna-Her2 More therapies…

    Learn about Your Condition

    Lichen sclerosus Cutaneous calcification Cortical dysplasia Cutibacterium acnes infection Post procedural hypotension Anogenital dysplasia Salivary gland cancer Retinoblastoma Primary myelofibrosis Endocarditis bacterial Biliary tract operation Benign renal neoplasm Blood disorder Asplenia Albright's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Dermatitis atopic

  • Study of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Triamcinolone Acetonide
    • Baricitinib
    • Hydrocortisone
    Austria Czechia France Germany Hungary Poland +1

  • Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Amlitelimab
    • Pimecrolimus
    • Tacrolimus
    Bulgaria Czechia Denmark Italy Portugal Spain +1

  • Study on the Safety and Effectiveness of ADX-914 for Patients with Moderate to Severe Atopic Dermatitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Bempikibart
    Poland

  • Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Lebrikizumab
    Austria Denmark France Italy Spain Sweden

  • Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Amlitelimab
    • Pimecrolimus
    • Tacrolimus
    France Germany Greece Poland

  • Study on Long-Term Safety and Effectiveness of Abrocitinib for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Abrocitinib
    Hungary Poland Spain
Previous Page
1 … 8 9 10 11 12 … 14
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!